The Law Offices of Vincent Wong announce that a class action lawsuit has
been commenced in the USDC for the Southern District District of New
York on behalf of investors who purchased Horizon Pharma plc (NASDAQ:
HZNP) securities between March 13, 2014 and February 26, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/horizon-pharma.
There is no cost or obligation to you.
The complaint alleges that throughout the Class Period, Defendants made
false and/or misleading statements and/or failed to disclose that: (i)
Horizon’s Prescriptions Made Easy (“PME”) program was designed to
artificially inflate the prices of minor differentiation standard retail
drugs; (ii) sales revenues from drugs sold through Horizon’s PME program
were unsustainable at these inflated price levels; and (iii) Horizon’s
use of its PME program left the Company subject to increased regulatory
risks.
On February 29, 2016, Horizon disclosed in its 2015 annual report that
the Company received a subpoena in November 2015 from the Office of the
U.S. Attorney for the Southern District of New York for documents and
information related to the Company’s patient assistance programs and
other aspects of Horizon’s sales and marketing activities
If you suffered a loss in Horizon you have until May
9, 2016 to request that the Court appoint you as lead
plaintiff. Your ability to share in any recovery doesn’t require that
you serve as a lead plaintiff. To obtain additional information, contact
Vincent Wong, Esq. either via email vw@wongesq.com,
by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/horizon-pharma.
Vincent Wong, Esq. is an experienced attorney that has represented
investors in securities litigation involving financial fraud and
violations of shareholder rights. Attorney advertising. Prior results do
not guarantee similar outcomes.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160328005631/en/
Copyright Business Wire 2016